Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to beat deadly fungus in blood cancer patients

NCT ID NCT07185503

Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a combination of two antifungal drugs—liposomal amphotericin B plus either posaconazole or isavuconazole—in 60 adults with blood cancers who also have a serious fungal infection called mucormycosis. The goal is to see if the combo can clear the infection better and with fewer side effects than standard treatments. Participants will be closely monitored for symptom improvement, side effects, and survival over several months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal amphotericin B combined with posaconazole or isavuconazole
What this could lead to
If this works, it could offer a more effective and safer treatment option for a deadly fungal infection in people with blood cancers.
What could go wrong
This is a small, early-phase study with only 60 participants and no comparison group. The combination may still cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Mucormycosis in Hematologic Malignancies patients

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of a hematologic malignancy (e.g., leukemia, lymphoma, myelodysplastic syndrome). * Proven, probable, or possible invasive mucormycosis according to the 2019 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria. * Age ≥18 years and ≤65 years at enrollment. * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2. * No clinically significant organ dysfunction (e.g., renal, hepatic, cardiac) at screening that would preclude protocol-defined therapies. * Ability to understand the study procedures and provide voluntary written informed consent. Exclusion Criteria: * Prior treatment with non-liposomal amphotericin B formulations (e.g., amphotericin B deoxycholate) for ≥4 days. * Documented hypersensitivity, severe immediate allergic reaction, or intolerance to liposomal amphotericin B. * History of a second malignancy (other than the index hematologic malignancy) treated within the past 3 years. * Active HIV infection, hepatitis B virus (HBV) infection (HBsAg-positive), hepatitis C virus (HCV) infection (RNA-positive), or syphilis. * Psychiatric disorders, cognitive impairment, or other conditions impairing compliance with study procedures or assessments. * Pregnant females, breastfeeding females, or individuals of reproductive potential unwilling to use effective contraception during treatment and for ≥3 months post-therapy. * Serum creatinine ≥2.0 × upper limit of normal (ULN). * Liver transaminases (ALT/AST) or alkaline phosphatase ≥5.0 × ULN. * Total bilirubin ≥3.0 × ULN (isolated bilirubin ≥3.0 × ULN is permitted if due to Gilbert's syndrome or hemolysis). * Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mucormycosis in hematologic malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    RECRUITING

    Tianjin, China

  • Second Hospital of Tianjin Medical University

    NOT_YET_RECRUITING

    Tianjin, China

  • Shengjing Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, China

  • The First Affiliated Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, China

  • The First Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, China

  • The Second Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, China

  • Tianjin First Central Hospital

    NOT_YET_RECRUITING

    Tianjin, 300020, China

  • Tianjin Haihe Hospital

    NOT_YET_RECRUITING

    Tianjin, China

  • Tianjin Union Medical Center of Nankai University

    NOT_YET_RECRUITING

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.